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Severity of Cardiovascular Disease Outcomes Among Patients With
HIV Is Related to Markers of Inﬂammation and Coagulation
Anna D. Nordell, BA; Matthew McKenna, BA; Alvaro H. Borges, MD, MSc; Daniel Duprez, MD, PhD; Jacqueline Neuhaus, MS;
James D. Neaton, PhD; for the INSIGHT SMART, ESPRIT Study Groups, and SILCAAT Scientiﬁc Committee*
Background-—In the general population, raised levels of inﬂammatory markers are stronger predictors of fatal than nonfatal
cardiovascular disease (CVD) events. People with HIV have elevated levels of interleukin-6 (IL-6), high-sensitivity C-reactive protein
(hsCRP), and D-dimer; HIV-induced activation of inﬂammatory and coagulation pathways may be responsible for their greater risk of
CVD. Whether the enhanced inﬂammation and coagulation associated with HIV is associated with more fatal CVD events has not
been investigated.
Methods and Results-—Biomarkers were measured at baseline for 9764 patients with HIV and no history of CVD. Of these
patients, we focus on the 288 that experienced either a fatal (n=74) or nonfatal (n=214) CVD event over a median of 5 years. Odds
ratios (ORs) (fatal versus nonfatal CVD) (95% conﬁdence intervals [CIs]) associated with a doubling of IL-6, D-dimer, hsCRP, and a
1-unit increase in an IL-6 and D-dimer score, measured a median of 2.6 years before the event, were 1.39 (1.07 to 1.79), 1.40
(1.10 to 1.78), 1.09 (0.93 to 1.28), and 1.51 (1.15 to 1.97), respectively. Of the 214 patients with nonfatal CVD, 23 died during
follow-up. Hazard ratios (95% CI) for all-cause mortality were 1.72 (1.28 to 2.31), 1.73 (1.27 to 2.36), 1.44 (1.15 to 1.80), and 1.88
(1.39 to 2.55), respectively, for IL-6, D-dimer, hsCRP, and the IL-6 and D-dimer score.
Conclusions-—Higher IL-6 and D-dimer levels reﬂecting enhanced inﬂammation and coagulation associated with HIV are
associated with a greater risk of fatal CVD and a greater risk of death after a nonfatal CVD event.
Clinical Trial Registration-—URL: http://www.clinicaltrial.gov Unique identiﬁer: SMART: NCT00027352, ESPRIT: NCT00004978,
SILCAAT: NCT00013611. ( J Am Heart Assoc. 2014;3:e000844 doi: 10.1161/JAHA.114.000844)
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O ver 15 years ago, an association between enhancedinﬂammation, as demonstrated by higher plasma levels
of C-reactive protein (CRP), and risk of coronary heart disease
(CHD) in middle-aged men without previous cardiovascular
disease (CVD) was reported using data from the Multiple Risk
Factor Intervention Trial (MRFIT).1 In MRFIT, CRP was strongly
related to CHD mortality, but was not related to nonfatal
myocardial infarction (MI). Importantly, most of the CHD
deaths occurred more than 10 years after the CRP measure-
ment. This MRFIT observation that markers of inﬂammation
are stronger predictors of fatal, as compared to nonfatal, CHD
events has been conﬁrmed in other studies.2–4 Reasons for
this ﬁnding include the possibility that patients with higher
inﬂammatory markers may have different underlying vascular
disease. It has been speculated that patients with greater
levels of inﬂammation might be more likely to experience fatal
arrhythmias that result in sudden death or have greater levels
of inﬂammation in unstable plaques.1–3 It is also possible that
low-grade inﬂammation results in activation of the coagulation
system, increasing the likelihood of fatal outcomes subse-
quent to plaque rupture.4 Other reasons include a greater
presence of other CVD risk factors among those with higher
inﬂammatory biomarker levels that increased risk of death, or
the presence of other nonvascular conditions that are
associated with chronic inﬂammation and that lead to an
increased risk of fatal events.
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Patients with HIV may contribute to our understanding of
these ﬁndings in the general population. They are in a
sustained inﬂammatory state even when taking suppressive
antiretroviral therapy (ART).5 Reasons for this inﬂammatory
state and the associated chronic state of immune activation
have been reviewed.6,7 Some key ﬁndings concerning HIV,
inﬂammation, and CVD, which we and others have described,
are: (1) compared to age- and gender-matched people in the
general population interleukin-6 (IL-6), high-sensitivity CRP
(hsCRP), and D-dimer are elevated5; (2) patients with HIV
appear to be at an increased risk of CVD, compared to
individuals without HIV8–12; and (3) IL-6, hsCRP, and D-dimer
measured several years beforehand are associated with all-
cause mortality and fatal or nonfatal CVD.1,13 The results in
the reports by Kuller and Duprez, which utilized stored plasma
specimens from the Strategies for Management of Antiretro-
viral Therapy (SMART) trial,14,15 also suggested that though
the associations of these biomarkers with fatal or non-fatal
CVD was similar to associations reported in general popula-
tion studies, the association with all-cause mortality was
stronger than for CVD, even though the deaths in SMART
were attributed to a number of different causes.
Collectively, these ﬁndings led us to formulate 2 hypoth-
eses: (1) HIV-positive patients with higher levels of IL-6,
hsCRP, and D-dimer, measured several years before the CVD
event, are more likely to experience a fatal, as compared to a
nonfatal, CVD event; and (2) mortality after nonfatal CVD
events is higher among HIV-positive patients with higher, as
compared to lower, levels of IL-6, hsCRP, and D-dimer, also
measured several years before the nonfatal event. To
investigate these hypotheses, we used data from SMART
and 2 other large international clinical trials of HIV
treatments.
Methods
Study Populations
This investigation included patients from 3 large international
HIV treatment trials conducted by the International Network
for Strategic Initiatives in Global HIV Trials, the SMART
trial,14,15 the Evaluation of Subcutaneous Proleukin in a
Randomized International Trial (ESPRIT),16,17 and the Subcu-
taneous Recombinant, Human Interleukin-2 in HIV-Infected
Patients with Low CD4+ Counts under Active Antiretroviral
Therapy (SILCAAT) trial.17 These trials were carried out in 33,
25, and 11 countries, respectively. The SMART study
compared continuous ART with intermittent ART among HIV-
positive patients with a CD4+ cell count of more than 350
cells/mm3. ESPRIT and SILCAAT compared IL-2 plus ART
versus ART alone among HIV-positive patients with CD4+
counts of 300 cells/mm3 or more and with CD4+ counts of 50
to 299 cells/mm3, respectively. All studies were approved by
an institutional review committee and patients were included
only after giving informed consent.
Biomarker Measurements
IL-6, hsCRP, and D-dimer were measured at baseline, before
randomization, in each trial using stored plasma for patients
who provided written consent. For patients in SMART, these
biomarkers were measured at the Laboratory for Clinical
Biochemistry Research at the University of Vermont (Burling-
ton). In the ESPRIT and SILCAAT trials, laboratory measure-
ments were performed by SAIC-Frederick (Frederick, MD). All
samples in both laboratories were analyzed blinded to
treatment group and CVD event status. IL-6 was measured
by the same method at each laboratory (Chemiluminescent
Sandwich ELISA; R&D Sytems, Minneapolis, MN). D-dimer
levels were measured by ELISA on the Sta-R analyzer, Liatest
D-DI (Diagnostic Stago, Parsippany, NJ), for patients in SMART
and on a VIDAS instrument (bioMerieux Inc, Durham, NC) for
patients in ESPRIT and SILCAAT. hsCRP was measured by
ELISA by both laboratories. For SMART, a NBTMII nephelom-
eter, N Antiserum to Human CRP (Siemens Diagnostics,
Deerﬁeld, IL), was used. For ESPRIT and SILCAAT, an R&D
Systems ELISA assay was used. Twenty samples were
independently analyzed at each laboratory for these biomar-
ker levels. Table S1 summarizes the measurements made at
each laboratory. Lower limits of detection (LLOD) for IL-6,
hsCRP, and D-dimer were 0.16 pg/mL, 0.16 lg/mL, and
0.01 lg/mL for SMART. In ESPRIT and SILCAAT, LLOD were
0.156 pg/mL, 0.078 lg/mL, and 0.045 lg/mL.
Baseline and Follow-up Measurements
In all 3 studies, the following baseline measurements were
obtained before randomization: age, sex, race, body mass
index (BMI), CD4+ cell count, HIV-RNA, duration of ART, and
previous AIDS clinical event. In SMART and ESPRIT, additional
baseline measurements were made, including hepatitis B/C
coinfection, diabetes, and use of blood pressure and lipid-
lowering medication. For patients in SMART, smoking status
was assessed and blood lipids were measured. During follow-
up, HIV RNA levels and CD4+ cell counts were recorded every
4 months in each study.
Events
CVD events considered were deaths attributed to CVD,
unwitnessed deaths that were not attributed to suicide, drug
abuse, or violence, nonfatal MI, nonfatal stroke, and coronary
artery disease (CAD) requiring surgery. In SMART and ESPRIT,
documentation of CVD events that was provided by the
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clinical sites were reviewed by an endpoint review committee
using prespeciﬁed criteria.18 Criteria for acute MI followed the
universal deﬁnition of MI.19 CAD requiring surgery required
a procedure report, hospital discharge summary, or other
medical record from the hospitalization during which the
procedure was performed (coronary artery bypass graft,
coronary artery stent implant, coronary artherectomy, or
percutaneous transluminal angioplasty). For strokes, 5 criteria
were considered: (1) acute onset with clinically compatible
course, including unequivocal objective ﬁndings of a localizing
neurological deﬁcit; (2) computed tomography (CT) or mag-
netic resonance imaging (MRI) compatible with diagnosis of
stroke and current neurologic signs and symptoms; (3) stroke
diagnosed as cause of death at autopsy; (4) positive lumbar
puncture compatible with subarachnoid hemorrhage; and
(5) death certiﬁcate or death note from medical record listing
stroke as the cause of death. A participant was considered to
have experienced a stroke if the ﬁrst and second criteria were
met, the third criterion was met, the ﬁrst and fourth criteria
were met, or the ﬁrst and ﬁfth criteria were met. In SILCAAT,
CVD events reported as serious adverse events were coded
according to the Medical Dictionary for Regulatory Activities
(MedRA; version 12.0). The following Standardized MedRA
Query codes were used for nonfatal stroke (20000082),
nonfatal MI (20000047), and CAD requiring surgery
(10068176, 10052086, 10057787, or 10063025). In all 3
studies, cause of death was coded using documentation of
the death provided by the clinical sites using the Coding of
Death in HIV system.20
In addressing our ﬁrst hypothesis, we deﬁned fatal CVD
events as: (1) deaths attributable to CVD or unwitnessed
deaths for patients that did not experience a nonfatal MI or
stroke before their death and (2) deaths within 28 days after
a nonfatal MI, stroke, or CAD. Patients who experienced MI,
stroke, or CAD events and survived at least 28 days were
deﬁned as having nonfatal CVD events.
For our second hypothesis, we considered any patient with
an MI, stroke, or CAD event who survived at least 28 days.
For this group of patients, we assessed subsequent risk of all-
cause mortality.
Statistical Analyses
Logistic regression, including indicators for study the patient
was enrolled in (SMART, ESPRIT, SILCAAT), was used to study
the association of each biomarker with fatal CVD. In addition
to considering each biomarker individually, we also consid-
ered a combined IL-6 and D-dimer score used for predicting
all-cause mortality among HIV patients with a suppressed viral
load. Because of their independent association with all-cause
mortality, the IL-6 and D-dimer score was created in order to
account for the contribution of both markers in a single
combined measure. This score was determined using the
control arms of SMART, ESPRIT, and SILCAAT (144 deaths)
and was adjusted for age, gender, and study; IL-6 and D-dimer
were log2 transformed. The regression coefﬁcients from this
Cox model for IL-6 and D-dimer were then used to create the
IL-6 and D-dimer score.21
In this investigation, the biomarkers were log2 transformed
because their distributions were right-skewed. With this
approach, a 1 log2 higher level of a biomarker corresponds
to a doubling of the marker. Results are also cited for tertiles
of each biomarker, which were deﬁned using all of the
patients in the 3 studies that experienced a fatal or nonfatal
CVD event. Other covariates, measured in each study, that
were considered potential confounding factors were: time
between biomarker measurement and the event, age, gender,
race, baseline BMI, HIV RNA level, baseline CD4+ cell count,
and earlier AIDS event at study entry. We also considered the
interaction between time between biomarker measurement
and the event with the log-transformed biomarker. In
sensitivity analyses, we adjusted for hepatitis B/C coinfec-
tion, diabetes, and use of blood pressure and lipid-lowering
medication (SMART and ESPRIT) and then added smoking and
the ratio of total cholesterol to high-density lipoprotein (HDL)
cholesterol (SMART only). We also carried out separate
analyses for patients in the control arms of the 3 studies.
These patients were to receive continuous ART with a goal of
suppressing HIV-RNA levels during follow-up. This is the
recommended standard of care for patients with HIV.22
Cumulative mortality after a nonfatal CVD event was
estimated using the Kaplan-Meier method. Cox models that
included study indicators were used to study factors related
to mortality for the 214 patients who experienced a nonfatal
CVD event. Models included the same covariates as the
logistic model, as well as CD4+ cell counts and HIV-RNA levels
both proximal to the nonfatal event. Hazard ratios (HRs) and
95% conﬁdence intervals (CIs) are cited. The proportional
hazards assumption was tested by including an interaction
term between each biomarker and log-transformed follow-up
time.
All analyses were performed using SAS statistical software
(version 9.2; SAS Institute Inc., Cary, NC). P<0.05 was
considered signiﬁcant.
Results
Among the 11 278 patients randomized in these trials (5472
SMART, 4111 ESPRIT, and 1695 SILCAAT), 10 001 (89%) had
IL-6, hsCRP, and D-dimer measured on stored baseline plasma
samples for consenting patients (5017 SMART, 3570 ESPRIT,
and 1414 SILCAAT). Of these, 9764 (98%) did not report a
history of CVD at study entry (Figure). Over a median
(interquartile range; IQR) follow-up of 5.0 (2.3, 7.1) years, 74
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of these 9764 patients developed fatal CVD; for 68 of these
patients, the CVD event reported was death (36 resulting from
CVD and 32 unwitnessed deaths); for 6 additional patients,
death occurredwithin 28 days of a nonfatal CVD event (3 after a
stroke and 3 after an MI). Two hundred and fourteen patients
experienced an MI, stroke, or CAD event and survived at least
28 days (102 MIs, 43 strokes, and 69 CADs requiring surgery).
Thus, 26% of CVD events (74 of 288) were fatal. The median
(IQR) time from biomarker measurement at baseline to the
event was 2.6 (1.1, 4.7) for fatal and non-fatal CVD events.
Comparison of Fatal and Nonfatal CVD Events
Baseline characteristics for patients according to the develop-
ment of a CVD event during follow-up and its severity are
summarized in Table 1. In these univariate analyses, IL-6,
D-dimer, and the IL-6 and D-dimer score were signiﬁcantly
greater for those patients who experienced a fatal, as compared
to a nonfatal, CVD event; hsCRP levels were also higher for
those with fatal events, as compared to nonfatal events, but the
difference was not signiﬁcant (P=0.26). Consistent with a
previous report,13 levels of all 3 of the biomarkers were higher
for patients who developed CVD, as compared to those who did
not. Difference in biomarker levels for those with and without a
CVD event, and by the severity of the CVD event, was consistent
across all 3 studies (Table 2). In regression models, we
considered the interaction of study with each biomarker and
none were signiﬁcant (P>0.40 for all). In the summary below,
we pool the results for the 3 studies.
When considered as continuous log2-transformed mea-
surements, higher levels of IL-6, D-dimer, and the IL-6 and D-
dimer score were associated with greater odds of a fatal CVD
event (Table 3). This was evident in uni- and multivariate
analyses. When tertiles were considered, signiﬁcant differ-
ences between the third and ﬁrst tertiles were found for IL-6,
D-dimer, and the IL-6 and D-dimer score. The risk gradient, as
judged by the odds ratio (OR) for a doubling of the biomarker
and based on the tertile analysis, tended to be strongest for
D-dimer and the IL-6 and D-dimer score and weakest for
hsCRP. Interactions of each biomarker and time between
10,001 patients with 
biomarker measurements
9,764 patients with no 
history of CVD at entry
288 patients with a CVD 
event during follow-up
8,766 patients with no 
CVD during follow-up
710 patients with no contact 
in the 12 months before 
study closure (unknown 
CVD status)
Exclusions
455 SMART
541 ESPRIT
281 SILCAAT
Exclusions
202 SMART
35 ESPRIT
0 SILCAAT
214 non-fatal 
events
74 fatal events
68 CVD 
deaths
6 deaths within 28 days of 
non-fatal event
23 deaths 191
survivors
11, 278 HIV + Patients
5,472 SMART
4,111 ESPRIT
1,695 SILCAAT
Figure. Flow diagram of patients included in analyses. CVD indicates cardiovascular disease; ESPRIT,
Evaluation of Subcutaneous Proleukin in a Randomized International Trial; SILCAAT, Subcutaneous
Recombinant, Human Interleukin-2 in HIV-Infected Patients with Low CD4+ Counts under Active
Antiretroviral Therapy; SMART, Strategies for Management of Antiretroviral Therapy.
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biomarker measurement and the event were also considered
and none were signiﬁcant. Sensitivity analyses were per-
formed, excluding the unwitnessed deaths, and results were
similar to those in Table 3. For example, univariate ORs (95%
CI) associated with a doubling of IL-6, D-dimer, hsCRP, and
the IL-6 and D-dimer score were 1.41 (1.03 to 1.92), 1.36
(1.01 to 1.82), 1.13 (0.92 to 1.37), and 1.50 (1.08 to 2.07),
respectively.
Considering the 206 patients (54 fatal and 152 nonfatal
events) in SMART and ESPRIT that had measurements
recorded at baseline, we adjusted for 4 additional covariates:
diabetes, hepatitis B/C coinfection, and use of blood pressure
and lipid-lowering medication. Adjusted ORs were similar to
those shown in Table 3: for IL-6, D-dimer, hsCRP, and IL and
D-dimer score, ORs (95% CIs) were 1.33 (95% CI, 0.95 to
1.86), 1.43 (95% CI, 1.02 to 2.00), 1.18 (95% CI, 0.95 to
1.47), and 1.49 (95% CI, 1.03 to 2.15), respectively.
For the 115 patients (31 fatal and 84 nonfatal events) in
SMART for whom we could also adjust for smoking and total/
HDL cholesterol, adjusted ORs were 1.10 (95% CI, 0.72 to
1.67), 1.39 (95% CI, 0.90 to 2.15), 1.25 (95% CI, 0.91 to
1.70), and 1.22 (95% CI, 0.78 to 1.93) for IL-6, D-dimer,
hsCRP, and the IL-6 and D-dimer score, respectively.
In SMART, the OR associated with a doubling of IL-6 was
lower than in analyses based on all 3 studies or based on
SMART and ESPRIT. For all 5017 patients in SMART, median
Table 1. Baseline Characteristics for HIV-Positive Patients Who Experienced CVD Events According to Severity
No Event* Fatal CVD† Nonfatal CVD‡ P Value§
Baseline characteristics, n 9476 74 214
Age (y), median (IQR) 42 (36 to 48) 48 (41 to 54) 49 (42 to 54) 0.76
Sex (% female) 22 14 8 0.21
Race (% black) 19 23 16 0.20
BMI (kg/m2), median (IQR) 24.3 (22.1 to 27.0) 24.0 (22.1 to 27.0) 24.3 (22.1 to 27.1) 0.58
CD4+ cell count, (cells/mm3) median (IQR) 487 (367 to 669) 409 (331 to 644) 469 (356 to 633) 0.63
HIV-RNA<500 copies/mL, % 77 74 77 0.64
Earlier AIDS event, % 26 39 29 0.10
IL-6, (pg/mL) median (IQR) 1.8 (1.2 to 2.8) 3.1 (1.9 to 4.5) 2.3 (1.5 to 3.5) 0.01||
% highest tertile (<1.88)# 20 45 28
% middle tertile (1.88≤9<3.14)# 27 31 36
% lowest tertile (≥3.14)# 52 24 36 0.02¶
D-dimer, (lg/mL) median (IQR) 0.24 (0.15 to 0.37) 0.35 (0.24 to 0.61) 0.27 (0.17 to 0.45) 0.006||
% highest tertile (<0.22) 21 45 29
% middle tertile (0.22≤9< 0.41) 31 32 34
% lowest tertile (≥0.41) 47 23 37 0.03¶
hsCRP, (lg/mL) median (IQR) 1.6 (0.7 to 3.6) 3.1 (1.1. to 7.5) 2.2 (1.1 to 5.6) 0.26||
% highest tertile (<1.55) 21 39 31
% middle tertile (1.55≤9<4.17) 29 32 34
% lowest tertile (≥4.17) 50 28 35 0.49¶
IL-6 and D-dimer score median (IQR) 0.02 (0.60 to 0.61) 0.85 (0.20 to 1.36) 0.30 (0.20 to 0.89) 0.003
% highest tertile (<1.04) 19 51 27
% middle tertile (1.04≤9<1.75) 28 26 36
% lowest tertile (≥1.75) 53 23 37 0.001¶
BMI indicates body mass index; CVD, cardiovascular disease; hsCRP, high-sensitivity C-reactive protein; IQR, interquartile range.
*No event measurements noted for completeness.
†Deaths attributed to CVD and unwitnessed deaths not resulting from violence, suicide, or drug abuse that were not proceeded by a nonfatal event or deaths within 28 days of the nonfatal
CVD event.
‡Nonfatal myocardial infarction, coronary artery disease requiring surgery, or nonfatal stroke for participants that survived at least 28 days.
§From a univariate logistic model comparing fatal and nonfatal CVD events (n=288).
||P values reported based on log2-transformed biomarker measurement.
¶P value based on 2 df chi-square test.
#Tertiles were deﬁned using all of the patients in the 3 studies that experienced a fatal or nonfatal CVD event.
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(IQR) levels of IL-6 for smokers and nonsmokers were 1.98
(1.19 to 3.23) and 1.65 (1.05 to 2.86), respectively (P<0.001
for difference). To investigate whether the adjustment for
smoking led to the lower OR for SMART, we compared
unadjusted and smoking adjusted ORs for SMART partici-
pants. In the unadjusted model, the OR associated with a
doubling of IL-6 was 1.29 (95% CI, 0.93 to 1.80); in the model
adjusting for smoking, the OR was 1.30 (95% CI, 0.93 to
1.81).
There were 134 patients in the control arms of the 3
studies that experienced a CVD event (32 fatal and 102
nonfatal). ORs were similar to those cited for all patients in
Table 3, but CIs were wider as a result of the smaller number
of events. Adjusted ORs (fatal/nonfatal events) were 1.62
(95% CI, 0.96 to 2.74), 1.40 (95% CI, 0.88 to 2.25), 1.11 (95%
CI, 0.82 to 1.51), and 1.89 (95% CI, 1.05 to 3.41) for IL-6,
D-dimer, hsCRP, and the IL-6 and D-dimer score, respectively.
Interaction P values for treatment/control and each biomar-
ker were all >0.59.
Biomarker Association With Mortality After a
Nonfatal CVD Event
Among the 214 patients who had a nonfatal CVD event, there
were 23 deaths (10.7%). Cumulative mortality 6 and
12 months after the nonfatal event for these patients, all of
whom survived at least 28 days, was 2.9% and 4.0%,
respectively.
In univariate analyses, higher levels of each of the
biomarkers were associated with an increased risk of death
(Table 4). HRs were reduced with covariate adjustment, yet
remained signiﬁcant for all 4 biomarkers. There was no
evidence that the proportional hazards assumption did not
hold for each biomarker (interaction P values all >0.73).
Discussion
Based on our previous work and studies in the general
population, we formulated 2 related hypotheses on the
association of inﬂammatory and coagulation markers and the
severity of future CVD events in HIV-positive patients. In
analyses that adjusted for HIV- and CVD-related factors, we
found that among HIV-positive patients who developed CVD:
(1) those with higher levels of IL-6, D-dimer, and an IL-6 and
D-dimer score, but not hsCRP, measured several years earlier
were signiﬁcantly more likely to have a fatal CVD event and
(2) the risk of death after an MI, stroke, or CAD event was
signiﬁcantly increased among HIV-positive patients with
higher baseline levels of IL-6, hsCRP, and an IL-6 and D-dimer
score, but not D-dimer. In this latter analysis, the biomarkers
Table 3. Unadjusted and Covariate Adjusted* Odds Ratios for Fatal CVD† (Versus Nonfatal CVD‡) According to Tertile and
Associated With a Doubling of Each Biomarker or 1-Unit Increase of IL-6 and D-Dimer Score
Biomarker
Lowest Tertile Middle Tertile Highest Tertile
OR Associated With Doubling of
Biomarker
OR OR 95% CI P Value OR 95% CI P Value Omnibus P Value§ OR 95% CI P Value
IL-6, pg/mL
Univariate 1.0 1.32 (0.66 to 2.64) 0.44 2.46 (1.25 to 4.87) 0.01 0.02 1.39 (1.07 to 1.79) 0.01
Adjusted 1.0 1.41 (0.69 to 2.88) 0.34 2.62 (1.26 to 5.46) 0.01 0.02 1.41 (1.07 to 1.86) 0.01
D-dimer (lg/mL)
Univariate 1.0 1.63 (0.80 to 3.33) 0.18 2.47 (1.25 to 4.85) 0.009 0.03 1.40 (1.10 to 1.78) 0.007
Adjusted 1.0 1.74 (0.80 to 3.75) 0.16 2.70 (1.27 to 5.75) 0.01 0.05 1.45 (1.10 to 1.92) 0.008
hsCRP (lg/mL)
Univariate 1.0 1.17 (0.60 to 2.29) 0.65 1.49 (0.77 to 2.88) 0.24 0.49 1.09 (0.93 to 1.28) 0.31
Adjusted 1.0 1.17 (0.59 to 2.33) 0.65 1.55 (0.78 to 3.10) 0.21 0.39 1.10 (0.93 to 1.30) 0.29
IL-6 and D-dimer
score
Univariate 1.0 1.15 (0.56 to 2.38) 0.71 3.07 (1.57 to 6.00) 0.001 0.001 1.51 (1.15 to 1.97) 0.003
Adjusted 1.0 1.20 (0.57 to 2.54) 0.64 3.67 (1.74 to 7.72) <0.001 <0.001 1.58 (1.17 to 2.13) 0.003
hsCRP indicates high-sensitivity C-reactive protein; OR, odds ratio.
*Covariates include: study indicators, log-transformed time to event, age, gender, race, body mass index, HIV-RNA, baseline CD4+ cell count, and earlier AIDS at baseline.
†Number of fatal CVD events=74.
‡Number of nonfatal CVD events=214.
§Based on 2 df chi-square test.
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were measured a median of 2.6 years before the nonfatal
event. To our knowledge, the prognostic importance of these
markers for fatal, as compared to nonfatal, CVD events has
not been studied in the setting of HIV infection.
Considering the results based on the ﬁrst hypothesis, our
ﬁndings are consistent with studies in the general population
that show an increased risk of more fatal CVD events for
patients with higher inﬂammatory markers. In MRFIT, higher
CRP levels at baseline were signiﬁcantly associated with CHD
death, all of which occurred 11 to 17 years after the CRP
measurement (P<0.001). No association (P=0.78) was found
between baseline CRP and nonfatal MIs, which occurred 6 to
7 years after CRP measurement.1 In the PROSPER study, IL-6
and CRP, measured at baseline in over 5000 patients, were
both more strongly related to fatal CVD events than nonfatal
CVD events.3 Engstr€om et al. measured 5 other inﬂammation-
sensitive plasma proteins (ISPs)—ﬁbrinogen, orosomucoid,
a1-antirypsin, haptoglobin, and ceruloplasmin—6075 healthy
men and found that, for men who subsequently developed a
coronary event, fatal events were related to the number of
ISPs measured at the baseline examination, which was an
average of 12.9 years before the events.2
In addition to IL-6, D-dimer, a ﬁbrin degradation product
and marker of ongoing coagulation, was signiﬁcantly associ-
ated with severity of CVD disease. We have previously shown
that D-dimer is elevated among patients with HIV infection.5
The signiﬁcant association of baseline D-dimer with severity
of CVD outcomes may reﬂect activation of coagulation
systems in response to low-grade inﬂammation associated
with HIV infection. It has been shown that HIV replication
alters the composition of extrinsic pathway coagulation
factors,23 and this cycle of inﬂammation and coagulation
resulting from infection may increase the risk of progressive
organ dysfunction and death.24,25
Higher levels of inﬂammatory markers and D-dimer for those
with fatal CVD may also reﬂect greater underlying disease. In
cross-sectional studies, higher D-dimer levels have been
associated with severity of peripheral atherosclerosis.26,27
In an overview of 3 studies, higher levels of IL-6 measured at
the time of stroke diagnosis were associated with an
increased risk of a poor outcome, including death,28 and
concluded that IL-6 may be a general marker of disease
severity. Although we excluded HIV-positive patients with a
history of CVD, recent cross-sectional comparisons of
HIV-positive men and women without a history of CVD with
HIV-negative controls have found differences in vascular
abnormalities.29–31 In 2 studies by the same group, those with
HIV were found to have more noncalciﬁed coronary plaque by
CT angiography.29,30 Furthermore, in one of these studies,
correlations between soluble CD163 and increased amount of
noncalciﬁed plaque suggests that monocyte and macrophage
activation may contribute to formation of vulnerable plaque in
HIV-positive patients.30 Thus, it is possible that those with
higher inﬂammatory markers had more vulnerable plaque
than those who did not. In another study,31 HIV-positive
patients without a history of CVD had more structural and
functional abnormalities based on cardiac MRI than HIV-
negative patients.
Studies in the general population have reported that higher
levels of markers of inﬂammation measured at the time of an
acute coronary event are related to subsequent mortality, but
not to recurrent coronary events.32–34 These observations
may be related to the ﬁndings of our second hypothesis, that
mortality after nonfatal CVD events would be higher among
HIV-positive patients with higher, as compared to lower, levels
of IL-6, hsCRP, and D-dimer. For patients in the general
population, De Servi et al. speculated that the highest
inﬂammatory markers observed during an acute coronary
syndrome are more likely to be observed among patients who
had high levels before the event.35 If HIV patients who are
already in a state of ongoing immune activation with chronic
low-grade inﬂammation are at increased risk of an exagger-
ated inﬂammatory response after their CVD event, as has
been suggested based on ﬁndings in the general population,3
this could explain the ﬁndings based on our second hypoth-
esis. However, we cannot directly address this because
Table 4. Unadjusted and Covariate Adjusted* Hazard Ratios for All-Cause Mortality After Nonfatal CVD† (n=214) Events
Associated With a Doubling of Biomarker or 1-Unit Increase in IL-6/D-Dimer Score
Biomarker
Median (IQR) Univariate Adjusted
Deaths (n=23) Survivors (n=191) HR 95% CI P Value HR 95% CI P Value
IL-6, pg/mL 3.1 (2.3 to 6.2) 2.2 (1.5 to 3.2) 1.72 (1.28 to 2.31) <0.001 1.85 (1.25 to 2.72) 0.002
D-dimer, lg/mL 0.47 (0.29 to 0.59) 0.27 (0.17 to 0.42) 1.73 (1.27 to 2.36) <0.001 1.76 (1.17 to 2.66) 0.007
hsCRP, lg/mL 5.3 (2.6 to 7.5) 2.0 (1.0 to 4.9) 1.44 (1.15 to 1.80) 0.001 1.39 (1.08 to 1.78) 0.01
IL-6 and D-dimer score 0.94 (0.37 to 1.57) 0.18 (0.25 to 0.72) 1.88 (1.39 to 2.55) <0.001 2.01 (1.35 to 3.01) <0.001
CVD indicates cardiovascular disease; hsCRP, high-sensitivity C-reactive protein; HR, hazard ratio.
*Covariates include: study indicators, log-transformed time to event, age, gender, race, body mass index, HIV-RNA at baseline and proximal to nonfatal CVD event, CD4+ cell count at
baseline and proximal to nonfatal CVD event, and earlier AIDS at baseline.
†Number of deaths after a nonfatal CVD event=23, including deaths attributed to CVD and unwitnessed deaths not resulting from violence, suicide, or drug abuse.
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biomarkers were not measured at the time of the nonfatal
CVD event.
There are several limitations to our ﬁndings. Cause of
death was uncertain for many of the deaths. However,
because sudden cardiac deaths account for most cardiac and
many non-AIDS deaths among HIV-positive individuals,36 we
found it reasonable to consider unwitnessed deaths not
attributable to suicide, drug abuse, or violence as fatal CVD.
In addition, we showed, in a sensitivity analysis, that results
did not differ when unwitnessed deaths were excluded from
the logistic models. Another limitation was that important
CVD risk factors at baseline were not fully assessed and could
only be partially adjusted for. ORs were reduced when only
SMART patients for whom smoking and blood lipids were
measured at baseline were considered. Although IL-6 levels
were higher among smokers than nonsmokers in SMART, the
percentages of patients with fatal and nonfatal events who
smoked were similar (Table 2), and ORs from unadjusted and
smoking-adjusted models were also similar, suggesting that
smoking was not an important confounding factor in studying
severity of CVD events. We also did not measure the
biomarkers in the time period immediately before events
occurred or at the time of the event. Correlations among
measurements taken more remotely with those proximal to
the event may be informative. Finally, power for both
hypotheses was limited, particularly for the analyses
restricted to the subgroup of patients who participated in
SMART, as well as for the patients in the control arms of the 3
studies, and, as a consequence, CIs are wide for those
analyses. Strengths include the central measurement of the
biomarkers, excellent follow-up, and the uniqueness of this
investigation in HIV-positive patients.
Conclusion
In conclusion, we sought to assess the prognostic value of
inﬂammatory and coagulation markers for fatal outcomes
among patients with HIV who experience CVD events. We
found that activated inﬂammatory and coagulation pathways,
as demonstrated by higher IL-6 and D-dimer plasma levels,
are associated with a greater risk of fatal, as compared to
nonfatal, CVD and a greater risk of death after a nonfatal CVD
event. These ﬁndings suggest that chronic inﬂammation and
activated coagulation associated with HIV leads to a poor
outcome when a CVD event occurs.
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